CARsgen Therapeutics Issues Clarification Announcement on Share Placement
Key Points:
- CARsgen Therapeutics Holdings Limited has issued a clarification announcement regarding its previous disclosure dated May 15, 2026 about a top-up placing and subscription of 23,700,000 shares.
- The clarification specifically adds a responsibility statement from the Board of Directors, confirming their joint and several responsibility for the accuracy and completeness of the information contained in the announcement.
- The Board assures investors that all opinions expressed were made after thorough and careful consideration, and that there are no undisclosed facts that would render any part of the announcement misleading.
Details Investors Should Know:
- The addition of the responsibility statement is a regulatory requirement and signals management’s confidence in the accuracy of the disclosure.
- The original announcement regarding the placement and subscription of 23,700,000 shares remains unchanged except for this new statement.
- The clarification comes from the Board, led by Chairman Dr. Zonghai LI. The Board comprises both executive and non-executive directors, as well as independent non-executive directors, whose names are clearly listed.
- The directors reiterate their accountability, which may enhance investor confidence in the company’s transparency and corporate governance standards.
Potential Impact on Share Price:
- This announcement is primarily procedural and does not introduce new price-sensitive information regarding the company’s business, financials, or strategy.
- However, it serves as an affirmation of the management’s responsibility and reliability, which can have a positive effect on investor sentiment, especially in light of recent share placements.
- No other changes to the original share placement announcement, which involved a significant number of shares, have been made. Investors should monitor for any further updates regarding the placement or subscription.
Board Composition:
- Executive Directors: Dr. Zonghai LI, Dr. Huamao WANG, Dr. Hua JIANG
- Non-executive Directors: Mr. Huaqing GUO, Mr. Ronggang XIE
- Independent Non-executive Directors: Dr. Guangmei YAN, Ms. Xiangke ZHAO, Dr. Wen ZHOU
Summary:
This clarification ensures regulatory compliance and reinforces the Board’s commitment to accurate and transparent communication with shareholders. While no new material information is disclosed, the affirmation of responsibility and completeness may be viewed positively by the market.
Disclaimer:
This article is intended for informational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Investors should conduct their own due diligence and consult with professional advisors before making any investment decisions.
CARsgen Therapeutics 發佈澄清公告 關於股份增發事項
重點摘要：
- CARsgen Therapeutics Holdings Limited 就2026年5月15日有關增發及認購23,700,000股股份的公告，發佈澄清公告。
- 澄清內容特別加入董事會的責任聲明，確認董事會對公告內容的準確性及完整性承擔共同及個別責任。
- 董事會向投資者保證，所有意見均經過仔細及合理的考慮，並且沒有任何未披露資訊會令公告內容有誤導成分。
股東需注意事項：
- 這份責任聲明屬監管要求，顯示管理層對披露資訊的信心。
- 原有關增發及認購23,700,000股股份的公告內容維持不變，只是補充了此責任聲明。
- 澄清公告由董事會主席李宗海博士發佈，董事會成員包括執行董事、非執行董事及獨立非執行董事，名單詳細列出。
- 董事會重申其問責承諾，有助提升公司透明度及企業管治水平，增強投資者信心。
對股價可能影響：
- 此公告屬程序性補充，未有披露任何新的價格敏感資訊。
- 但管理層承擔責任及承諾資訊準確，對市場信心具正面作用，尤其在近期股份增發背景下。
- 原增發公告未有其他變動，涉及大量股份，投資者需留意後續相關更新。
董事會組成：
- 執行董事：李宗海博士、王華茂博士、江華博士
- 非執行董事：郭華清先生、謝榮剛先生
- 獨立非執行董事：嚴光美博士、趙湘科女士、周文博士
總結：
此澄清公告旨在遵守監管要求，並加強董事會對準確及透明資訊披露的承諾。雖然未有披露新重要資訊，但責任聲明或會對市場情緒產生正面影響。
免責聲明：
本文僅供資訊參考，並不構成投資建議。投資者應自行審慎分析，並諮詢專業人士意見後作出投資決定。
